Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cohort Studies
  • Drug Administration Schedule
  • Female
  • Humans
  • Imidazoles / administration & dosage
  • Male
  • Melanoma / drug therapy*
  • Melanoma / enzymology
  • Melanoma / radiotherapy*
  • Middle Aged
  • Oximes / administration & dosage
  • Protein Kinase Inhibitors / administration & dosage
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Radiation-Sensitizing Agents / administration & dosage
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / enzymology
  • Skin Neoplasms / radiotherapy*
  • Treatment Outcome
  • Vemurafenib / administration & dosage
  • Young Adult

Substances

  • Imidazoles
  • Oximes
  • Protein Kinase Inhibitors
  • Radiation-Sensitizing Agents
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • dabrafenib